Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment

Journal of the American College of Cardiology

Volumn 31, Issue 7, 1998, Pages 1466-1473

  Gurbel, Paul A ^a   Serebruany, Victor L ^a   Shustov, Andrew R ^a   Bahr, Raymond D ^a   Carpo, Cynthia ^a   Ohman, E Magnus ^b   Topol, Eric J ^c  

^a UNION MEMORIAL HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALTEPLASE; CELL ADHESION MOLECULE; COLLAGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RETEPLASE; THROMBIN; VERY LATE ACTIVATION ANTIGEN 2;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; THROMBOCYTE AGGREGATION;

ADULT; AGED; ANTIGENS, SURFACE; BLOOD PLATELETS; FEMALE; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031747842     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00172-7     Document Type: Article

References (43)

1. Eccleston D., Topol E.J. Inhibitors of platelet IIb/IIIa as augmenters of thrombolysis. Coron Artery Dis. 6:1995;947-955.
2. Davies M.J., Thomas A.C., Knapman P.A., Hangarter J.R. Intramyocardial platelet aggregation in patients with acute myocardial infarction suffering sudden ischemic cardiac death. Circulation. 73:1986;418-427.
3. Luchessi B.R., Rote W.E., Driscoll E.M., Mu D.X. Prevention of thrombosis and rethrombosis and enhancement of thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Br J Pharmacol. 113:1994;1333-1343.
4. Nicolini F.A., Lee P., Rios G., Kottke-Marchant K., Topol E.J. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 89:1994;1802-1809.
5. Roux S.P., Tschopp T.B., Kuhn H., Steiner B., Hadvary P. Effects of heparin, aspirin and synthetic platelet glycoprotein IIb/IIIa receptor antagonist on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 264:1993;501-508.
6. Yasuda T., Gold H.K., Kohmura C., et al. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in canine preparations. Arterioscl Thromb. 13:1993;738-747.
7. Ohman E.M., Kleiman N.S., Gacioch G., et al. Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction results of a randomized, placebo-controlled, dose-ranging trial . Circulation. 95:1997;846-854.
8. Moliterno D.J., Harrington R.A., Krucoff M.W., et al. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI the PARADIGM trial [abstract] . Circulation. 94:(Suppl I):1996;I-553.
9. Rote W.E., Mu D.X., Bates E.R., Nedelman M.A., Lucchesi B.R. Prevention of rethrombosis after coronary thrombolysis in chronic canine model adjunctive therapy with monoclonal antibody 7E3 F(ab′) 2 fragment . J Cardiovasc Pharm. 23:1994;194-202.
10. Kohmura C., Gold H.K., Yasuda T., et al. A chimeric murine/human antibody Fab fragment directed against the platelet GP IIIa/IIb receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb Vasc Biol. 12:1993;1837-1842.
11. Kleiman N.S., Ohman E.M., Califf R.M., et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot study . J Am Coll Cardiol. 22:1993;381-389.
12. Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thromb Diath Haemorrh. 19:1968;474-482.
13. Terres W., Unmus S., Mathey D.G., Bleifeld W. Effects of streptokinase, urokinase, and tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. Cardiovasc Res. 67:1990;1175-1181.
14. Torr S.R., Winters K.J., Santoro S.A., Sobel B.E. The nature of interactions between tissue-type plasminogen activators and platelets. Thromb Res. 59:1990;279-293.
15. Golino P., Ashton J.H., Glas-Greenwalt P., McNatt J., Buja L.M., Willerson J.T. Mediation of reocclusion by thromboxane with tissue type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 77:1988;678-684.
16. Yao S.K., Ober J.C., Garfinkel L.I., et al. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation. 89:1994;2822-2828.
17. Fitzgerald D.J., Catella F., Roy L., Fitzgerald G.A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 77:1988;142-150.
18. Frandsen N.J., Winther K., Pedersen F., Christiansen I., McNair P. Time course of platelet α granule release in acute myocardial infarction treated with streptokinase. Heart. 75:1996;141-144.
19. Rasminis G., Vesterqvist O., Green K., Edhag O., Henriksson P. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J. 68:1992;374-376.
20. Salvoni A., Marenzi G., Lauri G., et al. β-Thromboglobulin plasma levels in the first week after myocardial infarction influence of thrombolytic therapy . Am Heart J. 128:1994;472-476.
21. Bertolino G., Noris P., Previtali M., et al. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol. 69:1992;457-461.
22. Bihor C., Durrieu-Jais C., Besse P., Nurden P., Nurden A.T. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis. 6:1995;395-410.
23. O'Brien J.R., Etherington M.D., Shuttleworth R.D., Calwell W.H. Platelet function in acute myocardial infarction patients compared to controls. Thromb Haemost. 44:1980;96-99.
24. Knudsen J.B., Gormsen J., Skagen K., Amtorp O. Changes in platelet function, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemost. 42:1979;1513-1522.
25. Lu J., Qi W., Shao H. Dynamic changes of the platelet granule membrane glycoprotein level in patients with acute myocardial infarction before and after thrombolysis. Chin J Intern Med. 34:1995;302-304.
26. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;33-42.
27. A comparison of reteplase and alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123.
28. Ruggeri Z.M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 31:1994;229-239.
29. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci. 677:1993;293-308.
30. Serebruany V.L., Ordonez J.V., Herzog W.R., et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 29:1997;16-22.
31. Smalling R.W., Bode C., Kalbfleisch J., et al. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction RAPID Investigators . Circulation. 91:1995;2725-2732.
32. Terres W., Lund G.K., Hubner A., Ehlert A., Reuter H., Mann C.W. Endogenous tissue-type plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusion. Am Heart J. 130:1995;711-716.
33. Coller B.S. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIb/IIIa receptors as antithrombotic therapy. Eur Heart J. 16:(Suppl I):1995;11-15.
34. Erickson L.A., Ginsberg M.H., Loskutoff D.J. Detection and partial characteristics of an inhibitor of plasminogen activator on human platelets. J Clin Invest. 74:1984;1465-1472.
35. 2-antiplasmin from human platelets. Blood. 58:1981;1069-1074.
36. Miles L.A., Plow E.F. Binding and activation of plasminogen on the platelet surface. J Clin Invest. 77:1986;2001-2009.
37. Vaughan D.E., Mendelson M.E., Declerck P.J., Van Houtte E., Collen D., Loscalzo J. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem. 264:1989;15869-15874.
38. Hoffmann J.J.M.L., Janssen W.C.M. Interactions between thrombolytic agents and platelets effects of plasmin on platelet glycoproteins Ib and IIb/IIIa . Thromb Res. 67:1992;711-719.
39. Adelman B., Michelson A.D., Loscalzo J., Greenberg J., Handin R.I. Plasmin effect on glycoprotein Ib-von Willebrand factor interactions. Blood. 65:1985;32-40.
40. Shafer A.I., Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest. 75:1985;456-461.
41. Kamat S.G., Michelson A.D., Benoit S.E., et al. Fibrinolysis inhibits shear stress-induced platelet aggregation. Circulation. 92:1995;1399-1407.
42. ++ dependent adhesion of platelets to collagen. J Cell Biol. 108:1989;1917-1924.
43. Newman P.J., Berndt M.C., Gorsky J., White G.C., Paddock L.S., Muller W.A. PECAM-1 (CD 31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 247:1990;1219-1223.